Last reviewed · How we verify
ASQ-3, Bayley III, Neurologic exam
ASQ-3, Bayley III, Neurologic exam is a Small molecule drug developed by AMAG Pharmaceuticals, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | ASQ-3, Bayley III, Neurologic exam |
|---|---|
| Sponsor | AMAG Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASQ-3, Bayley III, Neurologic exam CI brief — competitive landscape report
- ASQ-3, Bayley III, Neurologic exam updates RSS · CI watch RSS
- AMAG Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ASQ-3, Bayley III, Neurologic exam
What is ASQ-3, Bayley III, Neurologic exam?
ASQ-3, Bayley III, Neurologic exam is a Small molecule drug developed by AMAG Pharmaceuticals, Inc..
Who makes ASQ-3, Bayley III, Neurologic exam?
ASQ-3, Bayley III, Neurologic exam is developed by AMAG Pharmaceuticals, Inc. (see full AMAG Pharmaceuticals, Inc. pipeline at /company/amag-pharmaceuticals-inc).
What development phase is ASQ-3, Bayley III, Neurologic exam in?
ASQ-3, Bayley III, Neurologic exam is in Phase 2.